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Background: Gold nanorods (AuNRs), due to the optical and electronic properties namely the 
surface plasma resonance, have been developed to achieve the light-mediated photothermal therapy 
(PTT) for cancer. However, PTT alone may suffer from inefficient tumor killing. Recently, the 
combination of PTT and chemotherapy has been utilized to achieve synergistic anticancer effects. 
Methods: In this study, AuNRs capped with hexadecyltrimethylammonium bromide (CTAB), 
poly(acrylic acid) (PAA), and PEGylated anisamide (a ligand known to target the sigma receptor) 
have been developed to produce a range of negatively charged anisamide-targeted PEGylated 
AuNRs (namely Au-CTAB-PAA-PEG-AA) for the combination of PTT and chemotherapy 
(termed as chemo-photothermal therapy [CPTT]). Epirubicin (EPI, an anthracycline drug) was 
efficiently loaded onto the surface of Au
800




Results: The resultant complex demonstrated pH-dependent drug release, facilitated nucleus 
trafficking of EPI, and induced antiproliferative effects in human prostate cancer PC-3 cells. 
When Au
800
-CTAB-PAA-PEG-AA.EPI complex was further stimulated with desired laser 
irradiation, the synergistic outcome was evident in PC-3 xenograft mice.
Conclusion: These results demonstrate a promising strategy for clinical application of CPTT 
in cancer.
Keywords: gold nanoparticles, non-viral drug delivery, chemotherapy, photothermal therapy, 
synergistic effect
Introduction
Nanomaterial-assisted photothermal therapy (PTT) has recently emerged as a potential 
therapeutic strategy for solid tumors. Due to the optical and electronic properties 
namely the surface plasma resonance (SPR), gold nanoparticles (AuNPs) with specific 
structures, including gold nanorods (AuNRs),1 gold nanoshells,2 and gold nanocages,3 
have been developed to absorb light strongly in certain wavelengths and convert the 
light energy into heat, resulting in cancer cell death by apoptosis and/or necrosis.4 
Among these nanostructures, AuNRs demonstrate unique physicochemical proper-
ties, in that they may strongly absorb light in wavelengths between 650 and 900 nm 
within the near-infrared (NIR) region.5 It is known that for the light wavelengths 
between 650 and 2,000 nm, the tissue absorption is weak, and therefore tumors deeply 
seated within the body may be destroyed by PTT induced by AuNRs.6 However, the 
heterogeneous heat distribution inside the tumors caused by the uneven distribution 
of AuNRs has curtailed the PTT efficacy. Therefore, novel therapeutic strategies are 
required to facilitate synergistic effects when combined with PTT.
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Recently, the combination of PTT and other treatment 
modalities has presented great therapeutic potential for 
cancer. For instance, a variety of organic photosensitizers7,8 
can be loaded onto AuNRs; when photosensitizers are 
stimulated by the light of specific wavelengths, they convert 
the surrounding oxygen into toxic reactive oxygen species 
that may destroy cancer cells in surrounding proximity 
(known as photodynamic therapy [PDT]). The combina-
tion of AuNR-mediated PTT and photosensitizer-mediated 
PDT has demonstrated a significantly improved therapeutic 
efficacy.7 In addition, the combination of chemotherapy with 
AuNR-mediated PTT (chemo-photothermal therapy [CPTT]) 
has also been confirmed to be more effective than either 
of the individual monotherapies.9–16 However, the clinical 
application of CPTT is still retarded by significant delivery 
barriers, such as low drug loading efficiency, physiological 
instability, and lack of controlled drug release.6 Therefore, 
the development of AuNRs with great potential both in drug 
delivery and PTT is highly needed.
In this study, AuNRs with tunable longitudinal SPR 
(λ
max
 =700, 725, 765, and 800 nm) were initially synthesized 
in the presence of hexadecyltrimethylammonium bromide 
(CTAB), which promotes the growth of gold seeds in one 
direction, to produce positively charged gold nanorods 
(Au-CTAB) (Figure 1). The Au-CTAB was subsequently 
coated by poly(acrylic acid) (PAA) to generate negatively 
charged Au-CTAB-PAA. To improve physiological stability 
and target cancer cells, Au-CTAB-PAA was further modified 
with PEGylated anisamide (AA, a ligand known to target the 
sigma receptor overexpressed on a variety of human cancers, 
such as breast cancer, melanoma, non-small-cell lung carci-
noma, and prostate cancer)17–19 to achieve Au-CTAB-PAA-
PEG-AA (Figure 1). The Au-CTAB-PAA-PEG-AA was able 
to complex epirubicin (EPI, which is positively charged at 
physiological pH) via the electrostatic interaction forming 
Au-CTAB-PAA-PEG-AA.EPI complex. When stimulated 
with desired laser irradiation, the resultant complex of 
Au-CTAB-PAA-PEG-AA with EPI demonstrated signifi-
cantly greater antitumor effects in a prostate tumor xenograft 
mouse model when compared to either of the individual 
monotherapies, providing a promising CPTT strategy for 
cancer therapy.
Figure 1 a schematic representation of anisamide-targeted Pegylated auNrs for delivery of ePI to achieve photothermal therapy and chemotherapy in cancer.
Notes: (A) The scheme of anisamide-targeted auNr.ePI formulation. (B) Targeted formulation will specifically bind sigma receptor, a well-known molecule overexpressing 
on the cell membrane of prostate cancer cells, achieving cellular uptake via receptor-mediated endocytosis. ePI will be released from targeted formulation in acidic 
environments (ie, endosomes). Following endosomal escape with the assistance of NIr irradiation, auNrs may generate PTT, and ePI may enter the nucleus to induce 
chemotherapy. consequently, the synergistic anticancer effect will be achieved using anisamide-targeted auNr.ePI formulation.
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PC-3 (human prostate cancer cell line) was purchased 
from the American Type Culture Collection (ATCC, 
Rockville, MD, USA). Epirubicin was purchased from 
Dalian Meilun Biotechnology (Dalian, China). Tetrachlo-











), sodium borohydride 99% (NaBH
4
), silver nitrate 
(AgNO
3
) .99%, CTAB $98%, sodium salt of PAA with 
average Mw ~2,100 Da, O-[2-(3-mercaptopropionylamino)






hydrochloride (EDC⋅HCl), N-hydroxysuccinimide (NHS), 
N,N-diisopropylethylamine (DIPEA) purified by redistilla-
tion, dry dichloromethane (DCM), dry pentane, and magne-
sium sulfate (MgSO
4
) were purchased from Sigma-Aldrich 





O (resistivity =18.2 MΩ cm) was used as a solvent 
for AuNR synthesis. Glassware was cleaned with aqua regia 
(3 parts of concentrated HCl and 1 part of concentrated 
HNO
3
), rinsed with distilled water, ethanol, and acetone, 
and dried overnight before use.
Optical spectra
The optical absorption spectra were obtained using the 
Thermo Fisher™ Evolution™ 60S (Thermo Fisher Scientific, 
Waltham, MA, USA) UV-visible spectrophotometer with a 
xenon flash lamp (300–1,100 nm range, 0.5 nm resolution).
scanning electron microscopy (seM)
AuNRs were deposited onto a silicon wafer and air-dried 
prior to analysis using a FEI Quanta™ 650 equipped with an 
Oxford INCA energy-dispersive X-ray (EDX) detector oper-
ated at 5–20 kV and a high-resolution Helios DualBeam™ 
FIB Nanolab™ 600i equipped with an Oxford Aztec EDX 
detector operated at 5–30 kV.
Transmission electron microscopy (TeM)
AuNRs were deposited on carbon-coated copper grids (Ted 
Pella) and air-dried prior to TEM (JEOL JEM-2100 TEM 
operated at 200 kV). Images were recorded on a Gatan 
1.35 K × 1.04 K ×12 bit ES500W CCD camera.
Dynamic light scattering
Particle size and zeta potential were measured in deionized 
water (0.2 µm membrane filter) using the Malvern Nano-ZS 
(Malvern Instruments, Malvern, UK) at 25°C with the 
default non-invasive back scattering technique at a detection 
angle of 173°.
synthesis of auNr-cTaB
Synthesis of AuNR-CTAB seeds: AuNRs capped with 
CTAB were synthesized by seed-mediated growth method.20 
Briefly, 5 mL of 0.5 mM HAuCl
4
 solution was mixed with 
5 mL of 0.2 M CTAB solution. About 0.6 mL of 0.01 M 
NaBH
4
 freshly prepared in ice-cold water was added to the 
Au(III)-CTAB solution under vigorous stirring. The solu-
tion color changed to brownish yellow after the addition 
of NaBH
4
 and the reaction was stopped after 2 minutes. 
The seed solution was aged at room temperature (RT) for 
30 minutes before use.
Synthesis of AuNRs with longitudinal wavelength 
of ~800 nm: About 75 mL of 0.2 M CTAB solution was 
added to 3.75 mL of 4 mM AgNO
3
 solution at 25°C, which 
was followed by the addition of 75 mL of 0.001 M HAuCl
4
. 






 was added, and 
the solution color changed from dark yellow to colorless. 
Subsequently, 0.108 mL of the seed solution was added 
to the growth solution at 27°C–30°C. The solution color 
changed to reddish brown within 20–45 minutes. The growth 
medium was kept undisturbed at 27°C–30°C for 22 hours. 
The obtained AuNR-CTAB (hereafter referred to as Au
800
-
CTAB) was washed three times with deionized water by 
centrifugation (12,500 rpm, 5 minutes) prior to the following 
experiments.







-CTAB is described in the Supplementary materials.
synthesis of Nhs-activated anisic acid
NHS-activated anisic acid was produced as previously 
described.21 Briefly, EDC⋅HCl (1.5 eq, 1.9 g, 9.9 mmol) 
was added to the p-anisic acid solution (6.572 mmol) in 
dry DCM (250 mL) under argon, followed by the addition 
of NHS (1.45 eq, 1.1 g, 9.56 mmol). The reaction mixture 
was stirred for ~42 hours under Argon at RT. The organic 
phase was washed twice with water followed by a wash with 
brine, dried over MgSO
4
, filtered on Whatman filter paper, 
and evaporated. The activated ester thus obtained was left 
to stir in 30 mL of dry pentane for ~48 hours, filtered, dried 
under vacuum, and used without further purification. The 
yield of the anisic-NHS ester (AA-NHS) was ~90%. The 
product was analyzed using nuclear magnetic resonance 
(NMR) spectroscopy ([400 MHz, CDCl
3
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 in NHS ring]).21
synthesis of Pegylated anisamide (sh-Peg5000-aa)




 (0.02 mmol) was 
dried under the vacuum for 10 minutes at RT, followed by 
the application of a flow of nitrogen (N
2
), and further dried 





powder was then dissolved in 4 mL of DCM under N
2
 and 
2 mL of AA-NHS (0.034 mmol) in dry DCM was added and 
stirred at 0°C. Subsequently, 50 µL of DIPEA (0.688 mmol) 
in dry DCM was added and stirred under N
2
 at RT for 
48 hours. The resultant SH-PEG
5000
-AA was precipitated 
at 0°C using 100 mL of cold diethyl ether/ethanol solution 
(v/v =99/1). The SH-PEG
5000
-AA was collected at 0°C by 
centrifugation at 11,000 rpm and dried overnight under the 
vacuum. The SH-PEG
5000
-AA (~90% yield) was character-
ized by NMR in CDCl
3
: δ ppm 7.79–7.81 (d, 2H, ArH-CO-), 







 of PEG), 2.9 (CH
2
-C=O). The degree of 
anisamide attachment was ~100% as calculated from the 
peak integration ratio of phenyl proton at δ 7.78 to methylene 
protons at δ 3.65.
synthesis of auNr-cTaB-Paa, auNr-cTaB-Paa-
Peg, and auNr-cTaB-Paa-Peg-aa
The resultant AuNR-CTAB was added into PAA solution 
(0.1–0.15 mM) at concentrations of 100–190 µg/mL to pro-







-AA (4 µM) was added into AuNR-CTAB-
PAA to produce the final formulation Au-CTAB-PAA-PEG 










Preparation and physicochemical 
characterization of auNr.ePI complex
In order to form AuNR.EPI complex, AuNRs (100 µg) were 
added to EPI solutions (0.5 µg/µL in 0.01 M PBS at pH =7.4) 
at different mass ratios (MRs), followed by 12-hour incuba-
tion with 400 rpm shaking at 45°C. Following incubation, 
the uncomplexed EPI was removed by centrifugation at 
6,000 rpm for 20 minutes and measured using UV-visible 
spectrophotometer at 480 nm, in order to determine the 
efficiency of AuNRs to form complex with EPI. Particle size 
and zeta potential of AuNR.EPI complex were assessed using 
the Malvern Nano-ZS as described in the section “Dynamic 
light scattering”.
In addition, the AuNR.EPI complex (MR =5) was 
incubated within the saline at 4°C and 37°C for 6, 24, and 
48 hours. The particle size and zeta potential of AuNR.
EPI complex were assessed using the Malvern Nano-ZS as 
described in the section “Dynamic light scattering”.
To evaluate the photothermal conversion efficiency, 
200 µL of PBS, EPI (0.2 µg/µL), blank AuNRs (1 µg/µL), 
and AuNR.EPI formulation (AuNR =1 µg/µL; MR =5) 
were irradiated by 808 nm NIR laser with an intensity of 
2.5 W/cm-2 (BWT; Diode Laser System, Beijing, China). 
The temperature change was monitored by the infrared 
thermal analysis system (BM_IR; Beetech, Beijing, China) 
for 4.5 minutes at an interval of 0.5 min per reading.




-CTAB-PAA-PEG-AA.EPI complex (MR =5) was 
incubated in 0.01 M PBS (pH =5.5 and 7.4) at 37°C with 
400 rpm shaking for 0.5, 1, 2, 4, 6, 12, 24, and 48 hours. 
At predetermined time intervals, the solution was centrifuged 
at 6,000 rpm for 20 minutes. About 200 µL of the supernatant 
was collected and replaced with the same volume of fresh 
release medium. The cumulative release rate of EPI was 
evaluated using high-performance liquid chromatography 
(SPD-20A; Shimadzu) at 480 nm.
cellular uptake
PC-3 cells were maintained in RPMI-1640 medium (Corning 
Incorporated) supplemented with 10% FBS (heat inacti-
vated; Thermo Fisher Scientific, Waltham, MA, USA) and 
1% penicillin-streptomycin nystatin solution (Biological 
Industries). Cells (5×104 per well) were seeded in 24-well 






(5 µg/mL) and incubated for 8 hours under normal growth 
conditions. Following incubation, cells were washed twice 
with PBS. Fresh growth medium was added to the cells prior 
to confocal microscopic analysis using an LSM 800 Zeiss 
confocal microscope (40×).





-CTAB-PAA-PEG-AA (5 µg/mL) con-
taining EPI (MR =5) and incubated for 4 hours under normal 
growth conditions. After this, cells were washed twice with 
PBS and trypsinized. After 1,000 rpm centrifugation for 
5 minutes, the supernatant was discarded and cells were 
resuspended in 1,000 µL of ice-cold PBS. About 10,000 
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for each sample using flow cytometry (Becton Dickinson 
FACS-Canto II).
Intracellular trafficking
PC-3 cells were seeded in six-well culture plates with 
cover slip (CITOGLAS®, China) (2×105 cells per well) for 
24 hours. Cells were then treated with EPI (1 µM) complexed 
with Au
800
-CTAB-PAA-PEG-AA (MR =5) with/without 
laser irradiation (808 nm at 2.5 W/cm2 for 0.5 minutes). 
Following 4 hours of incubation, cells were incubated in 
LysoTracker™ Green DND-26 (75 nM; Thermo Fisher 
Scientific) at 37°C for 30 minutes. Cells were washed twice 
with PBS and fixated with 350 µL paraformaldehyde (4%) in 
PBS for 20 minutes. Cells were then washed three times with 
PBS and treated with the mounting agent (SouthernBiotech). 
The confocal microscopic analysis was carried out using an 
LSM 800 Zeiss confocal microscope.
In vitro anticancer effects of auNr.ePI 
complex
PC-3 cells (1×105 cells per well) were seeded in 24-well 
culture plates. Following 24 hours of incubation, cells were 
added by anisamide-targeted AuNRs (MR =5) complexed 
with or without 1 µM EPI for 12 hours. After this, cells 
were replaced with fresh growth medium and stimulated 
with 808 nm laser at 2.5 W/cm2 for 0.5 minutes. Cells were 
further incubated for 12 hours under normal growth condi-
tions. Subsequently, cells were lysed using RIPA buffer 
(50 mM Tris [pH 7.4], 150 mM NaCl, 1% NP-40, 0.5% 
sodium deoxycholate, 1% SDS, sodium orthovanadate, 
sodium fluoride, EDTA, and leupeptin), and protein con-
centrations were quantified using the Easy II BCA Protein 
Quantitative Kit (GenStar). Approximately 30–50 µg of 
proteins per sample was loaded onto an SDS-PAGE and 
electrophoresed at 80 V for 0.5 hours and subsequently 
at 120 V for 1.5 hours. Proteins were then transferred to a 
PVDF membrane (Immobilon®-P Transfer Membrane; EMD 
Millipore, Billerica, MA, USA) at 200 mA for 1.5 hours. 
Membranes were incubated with appropriate antibodies 
(caspase 3 [AF6311], cleaved caspase 3 [AF7022], caspase 9 
[AF6348], cleaved caspase 9 [AF5240], Bax [AF0120], Bcl-2 
[AF6139], and β-actin [AF7018], purchased from Affinity 
Biosciences, Cincinnati, OH, USA) at RT for 12 hours. Anti-
body reactive bands were detected using MicroChemi (DNR 
Bio-Imaging Systems Ltd., Jerusalem, Israel). Densitometry 
analysis of bands was performed using ImageJ, and all results 
were normalized to the β-actin control.
In addition, PC-3 cells (5×103 per well) were seeded in 
96-well plates for 1 day. After this, cells were treated with 
EPI (1 µM), Au-CTAB-PAA-PEG (MR =5) complexed with 
or without EPI, and Au-CTAB-PAA-PEG-AA (MR =5) 
complexed with or without EPI. After 8 hours of incubation, 
cells were replaced with fresh growth medium and stimulated 
with 808 nm laser at 2.5 W/cm2 for 0.5 minutes. Cells were 
further incubated for 24 and 48 hours under normal growth 
conditions. Cells were then added with 20 µL MTT stock 
(5 mg/mL in PBS) in 200 µL of fresh growth medium and 
incubated for 3–4 hours at 37°C. About 150 µL of DMSO 
was added to dissolve the purple formazan products. The 
results were read at 570 nm using microplate reader.
In vivo antitumor efficacy of AuNR.EPI 
complex
All animals received care in compliance with the guidelines 
outlined in the Guide for the Care and Use of Laboratory 
Animals. The animal ethics committee of Jilin University 
approved all experiments. All mice were maintained in a 
pathogen-free animal facility for at least 2 weeks before the 
experiments.
Male BALB/c nude mice (5–6 weeks) were purchased 
from Beijing Vital River Laboratory Animal Technology Co., 
Ltd. The xenograft mice were established by subcutaneous 
injection of 5×106 PC-3 cells into the flank of animals. The 
tumor volume was calculated using the formula a2b(π/6), 
where a is the minor diameter of the tumor and b is the 
major diameter perpendicular to diameter a. When the tumor 
reached a volume of ~200 mm3 (day 0), mice (n=4 per group) 
were intratumorally injected at days 1, 3, 5, 7, and 9 with 
saline, Au
800
-CTAB-PAA-PEG-AA (2.5 mg/kg) followed 
by 808 nm laser stimulation at 2.5 W/cm2 for 2 minutes, 
and Au
800
-CTAB-PAA-PEG-AA (MR =5) containing EPI 
(0.5 mg/kg) with or without the 808 nm laser stimulation at 
2.5 W/cm2 for 2 minutes. Tumor growth and body weight 
were recorded regularly, and the tumor volume was calcu-
lated as described earlier.
statistical analyses
Data were calculated as the mean ± SD. An unpaired 
Student’s t-test (two-tailed) was used to test the significance 
of differences between two mean values. A one-way ANOVA 
(Bonferroni’s post hoc test) was used to test the significance 
of differences in three or more groups. In addition, a two-way 
ANOVA (Bonferroni’s post hoc test) was used to test the 
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pharmacokinetics, and tumor growth. In all experiments, 
P,0.05 was considered statistically significant.
Results and discussion
synthesis and physicochemical 
characterization of auNrs
Recently, nanomaterial-based PTT has demonstrated great 
potential for cancer therapy.22 AuNRs, due to the tunable 
and sensitive SPR, have been developed to absorb the NIR 
irradiation for light to heat conversion,23 providing the 
thermal ablation of malignant cells (more thermosensitive 
cells),24 while causing less subversion to the surrounding 
healthy cells.
In this study, AuNRs with tunable longitudinal SPR 
(λ
max
 =700–800 nm) were initially synthesized via seeding 
growth method in the presence of CTAB as shape directing 
agent to produce positively charged Au-CTAB (Figures 2A, 
B and S1). The formation of Au-CTAB was confirmed by 
UV-vis spectroscopy indicating that AuNR-CTAB had dif-
ferent maximum of absorption at 700, 725, 765, and 800 nm, 
respectively, with different aspect ratios (Figure 2C). These 
Au-CTAB NPs were subsequently coated by a polyelectro-
lyte PAA to generate negatively charged Au-CTAB-PAA. 
As shown in Figure 2D, Au
800
-CTAB-PAA demonstrated a 
negatively charged surface (-47 mV) compared to Au
800
-
CTAB (40 mV), indicating the successful deposition of 
anionic PAA onto the cationic surface of Au-CTAB.
Sigma receptors are well known to overexpress on the 
membrane of various human cancer cells (eg, breast cancer, 
melanoma, non-small-cell lung carcinoma, and prostate 
cancer).25,26 Recently, NPs modified with anisamide or 
anisamide derivatives for targeting sigma receptors have 
shown promise for efficient drug delivery in the treatment 






PEG-AA were -18 mV and -25 mV respectively, which 
were significantly higher than that of Au
800
-CTAB-PAA 
(-47 mV), indicating that the surface of Au-CTAB-PAA 







-AA (Figures S2 and S3). In addition, a “halo-like” 
layer was clearly observed on the surface of Au-CTAB-
PAA-PEG-AA (Figure 2E), most likely due to the attachment 
Figure 2 (A) seM of au800-cTaB (scale bar =400 nm); (B) TeM of au800-cTaB (scale bar =50 nm); (C) UV-vis spectrum of au700-cTaB, au725-cTaB, au765-cTaB, and au800-
cTaB; (D) zeta potential of au800-cTaB, au800-cTaB-Paa, au800-cTaB-Paa-Peg, and au800-cTaB-Paa-Peg-aa obtained using the Malvern Nano-Zs; (E) high-energy 
seM of au800-cTaB-Paa-Peg-aa (scale bar =200 nm).
Abbreviations: auNrs, gold nanorods; seM, scanning electron microscopy; cTaB, hexadecyltrimethylammonium bromide; Paa, poly(acrylic acid); aa, anisamide; 
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-AA. Therefore, these results show that the 
PEGylated anisamide was successfully conjugated onto 
the surface of Au-CTAB-PAA forming Au-CTAB-PAA-
PEG-AA. In addition, the PEGylated AuNRs were stable 
for .1 year when stored in the dark at 4°C.
Formulation and physicochemical 
characterization of auNr.ePI complex
Doxorubicin (DOX) is a commonly used chemotherapeutic 
for a diverse set of human cancers, and can result in antipro-
liferative actions by blocking the topoisomerase I/II activity 
and by intercalating into DNA. DOX, due to cationic property 
in physiological environments,34 could be loaded onto the 
surface of negatively charged NPs. EPI (an epimer of DOX) 
has similar therapeutic efficacy with DOX, but causes less 
cardiotoxicity and myelosuppression compared to DOX.35 
Therefore, EPI was chosen to achieve the complexation with 
Au-CTAB-PAA-PEG-AA via the electrostatic interaction.
The complexation efficiency of EPI with PEGylated 
AuNRs was optimized at MR 5 of AuNRs and EPI. As shown 





PEG-AA demonstrated ~90% complexation efficiency of EPI 






is interesting to note that aggregation occurred to PEGylated 
AuNRs with λ
max
 =725 and 765 nm (Table 1). In comparison 
to AuNRs, the net charges of AuNR.EPI complexes were 
significantly increased when complexed with EPI (~10 mV) 
(Table 1). These results indicate that cationic EPI was electro-
statically complexed onto the anionic surface of PEGylated 
AuNRs. On the basis of the physicochemical results, the 
complexes of Au
800
-CTAB-PAA-PEG-AA with EPI at MR 5 
were used for the following in vitro and in vivo experiments.
The SPR is dependent on size and shape of AuNRs, 
and therefore the morphological stability of AuNRs is of 
importance for PTT application. The incorporation of PEG 
into NPs is known to enhance the stability in physiological 
environments.36,37 In this study, when PEGylated AuNR.
EPI complexes (MR =5) were incubated with saline at 4°C 
and 37°C, no significant NP aggregation was observed up 
to 48 hours (Figure S4), implying the ability of PEGylated 
AuNR.EPI complexes to stabilize nanostructures in vitro 
and in vivo.
A safe and efficient delivery system allows drug release 
inside cancer cells, but avoids burst release during blood 
circulation. In order to investigate the release profiles, EPI 
complexed with Au
800
-CTAB-PAA-PEG-AA was incubated 
with 0.01 M PBS (pH =5.5 and 7.4) at 37°C with 400 rpm 
shaking. As shown in Figure 3, no burst release of EPI from 
anisamide-targeted AuNRs was observed at pH =7.4, and in 
contrast, a pH change from 7.4 to 5.5 significantly increased 
the release rate (by approximately fourfold). These results 
suggest that anisamide-targeted AuNRs may avoid the burst 
release of EPI in the physiological environments (pH =7.4) 
but facilitate the drug release inside endosomes (pH =5.5) 
of cancer cells.
Table 1 Physicochemical characterization of auNrs and auNr.ePI complexes (Mr =5) (n=5)
AuNRs Particle size (nm) Zeta potential (mV) Complexation efficiency (%)
au700-cTaB-Paa-Peg 25±1 (PDI =0.174) -21±1 N/T
au700-cTaB-Paa-Peg.ePI 80±2 (PDI =0.235) -6±2 68±5
au700-cTaB-Paa-Peg-aa 33±2 (PDI =0.152) -20±1 N/T
au700-cTaB-Paa-Peg-aa.ePI 85±2 (PDI =0.260) -5±2 65±3
au725-cTaB-Paa-Peg 22±1 (PDI =0.174) -18±2 N/T
au725-cTaB-Paa-Peg.ePI aggregation N/T N/T
au725-cTaB-Paa-Peg-aa 31±1 (PDI =0.174) -17±2 N/T
au725-cTaB-Paa-Peg-aa.ePI aggregation N/T N/T
au765-cTaB-Paa-Peg 24±3 (PDI =0.184) -17±3 N/T
au765-cTaB-Paa-Peg.ePI aggregation N/T N/T
au765-cTaB-Paa-Peg-aa 35±3 (PDI =0.182) -19±3 N/T
au765-cTaB-Paa-Peg-aa.ePI aggregation N/T N/T
au800-cTaB-Paa-Peg 24±3 (PDI =0.170) -22±3 N/T
au800-cTaB-Paa-Peg.ePI 82±2 (PDI =0.235) -5±1 91±2
au800-cTaB-Paa-Peg-aa 36±2 (PDI =0.160) -19±2 N/T
au800-cTaB-Paa-Peg-aa.ePI 90±2 (PDI =0.229) -5±1 90±3
Abbreviations: auNrs, gold nanorods; ePI, epirubicin; Mr, mass ratio; PDI, polydispersity index; N/T, not tested; cTaB, hexadecyltrimethylammonium bromide; 
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cellular uptake and intracellular 
trafficking
PC-3, a sigma receptor overexpressing cell line,19,21,38,39 was 
therefore chosen to investigate in vitro and in vivo potential 
of anisamide-targeted AuNRs. AuNPs are known as a very 
useful contrast agent and can be visualized using differential 
interference contrast (DIC) microscopy.40 Indeed, DIC 
microscopy has been commonly used to investigate the 
cellular uptake of AuNPs.41–43 As shown in Figure 4A, DIC 
images demonstrate that anisamide-targeted AuNRs (detected 
as dark dots)41–43 significantly enhanced the uptake into PC-3 
cells relative to untreated cells or cells treated with non-
targeted counterparts in which minor AuNRs were observed 
(Figure 4A), suggesting a receptor-mediated cellular uptake 
due to the attachment of anisamide targeting ligand.
In addition, EPI was used to further investigate the cel-
lular uptake of Au
800
-CTAB-PAA-PEG-AA complex in PC-3 
cells (Figure 4B).44 The results of flow cytometry displayed 
a significantly higher cellular uptake of anisamide-targeted 
AuNR.EPI formulation when compared to untreated group 
and non-targeted AuNR.EPI formulation (Figure 4B). 
These results further confirm that grafting of anisamide may 
enhance targeting of AuNRs to PC-3 cells through the sigma 
receptor-associated pathway.
Following ligand–receptor mediated internalization, 
NPs are normally transported into endosomes in which the 
pH becomes ~5–6. It is known that DOX, as a basic che-
motherapeutic, is membrane permeable in the neutral form 
Figure 3 The in vitro release of ePI from au800-cTaB-Paa-Peg-aa (Mr =5) in 
ph =5.5 and 7.4 at 37°c with 400 rpm shaking (n=5; ***P,0.001).
Abbreviations: au, gold; ePI, epirubicin; Mr, mass ratio; cTaB, hexadecyltrimethyl-
ammonium bromide; Paa, poly(acrylic acid); aa, anisamide; Peg, polyethylene 
glycol.
Figure 4 cellular uptake of anisamide-targeted auNrs in Pc-3 cells was measured using (A) confocal microscopy and (B) flow cytometry.
Note: The images were acquired using an lsM 800 Zeiss confocal microscope (40×).
Abbreviations: auNrs, gold nanorods; ePI, epirubicin; cTaB, hexadecyltrimethylammonium bromide; Paa, poly(acrylic acid); aa, anisamide; Peg, polyethylene glycol.
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but relatively impermeable when protonated.45 Therefore, 
when DOX or EPI enter into acidic endosomes, they become 
protonated and are subsequently sequestered.46 As shown 
in Figure 5, a definite fraction of EPI (red) was detected 
inside endosomes/lysosomes (green) (as indicated by yellow 
arrows) for targeted AuNR.EPI complex (MR =5). It has 
been reported that photothermal activation can be employed 
to enhance endosomal escape of therapeutic cargos.47,48 
As shown in Figure 2, Au
800
-CTAB-PAA-PEG-AA exhib-
ited a SPR in response to the wavelength of 800 nm. When 
stimulated with laser irradiation at 808 nm, 2.5 W/cm2 for 





-CTAB-PAA-PEG-AA.EPI was increased 
to ~55°C and ~65°C, respectively (Figure S5), and such 
temperature is sufficient for hyperthermal effect. Indeed, 
following the laser irradiation, no obvious co-localization 
of red and green fluorescence was evident in cells treated 
with targeted AuNR.EPI complex (Figure 5), indicating the 
potential of AuNR-based photothermally induced endosomal 
release of EPI.
In vitro anticancer efficacy
To investigate the capacity of anisamide-targeted AuNR.
EPI formulation to induce apoptosis, the expression of Bcl-2 
and Bax and the activity of caspases 9 and 3 were assessed 
using Western blotting of PC-3 cells (Figures 6 and S6). 
The expression of Bcl-2 (one anti-apoptotic mediator)49 
was significantly reduced by anisamide-targeted AuNR. 
EPI formulation (Figures 6 and S6). It has been reported 
that thermal therapy (also called hyperthermia) may 
increase the sensitivity of cancer cells to DOX and EPI,50 as 
hyperthermia can retard the repair of DNA damage caused 
by anthracycline antibiotics.51 Indeed, when stimulated with 
β
Figure 6 The expression of caspase 3, cleaved caspase 3 (phosphorylated form), 
caspase 9, cleaved caspase 9 (phosphorylated form), Bcl-2, Bax, and β-actin was 
determined using Western blotting.
Note: Untreated = untreated cells; auNr-aa + laser = au800-cTaB-Paa-Peg-aa 
plus laser irradiation; auNr-aa.ePI = au800-cTaB-Paa-Peg-aa.ePI; and auNr-
aa.ePI + laser = au800-cTaB-Paa-Peg-aa.ePI plus laser irradiation.
Abbreviations: auNrs, gold nanorods; ePI, epirubicin; cTaB, hexadecyltrimethyl-
ammonium bromide; Paa, poly(acrylic acid); aa, anisamide; Peg, polyethylene 
glycol.
Figure 5 Intracellular distribution of anisamide-targeted auNrs in Pc-3 cells.
Notes: Pc-3 cells were treated with 5 µg/ml of au800-cTaB-Paa-Peg or au800-CTAB-PAA-PEG-AA and incubated for 4 hours. A definite fraction of EPI (red) was detected 
inside endosomes/lysosomes (green) (as indicated by yellow arrows) for targeted auNr.ePI complex (Mr =5). Following the laser irradiation at 808 nm at 2.5 W/cm2 for 
0.5 minutes, no obvious co-localization of red and green fluorescence was evident in cells treated with targeted AuNR.EPI complex, and EPI was clearly found inside the 
nucleus. The images were acquired using an lsM 800 Zeiss confocal microscope (40×).
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laser irradiation, EPI complexed with anisamide-targeted 
AuNRs further reduced the expression of Bcl-2 (Figures 6 
and S6). It is known that Bcl-2 is functional to restrain 
pro-apoptotic Bax/Bak.49 Following the downregulation of 
Bcl-2, the expression of Bax was significantly enhanced 
by anisamide-targeted AuNR.EPI complex plus laser irra-
diation (Figures 6 and S6). It is known that Bax can acti-
vate caspase 9, and once activated, caspase 9 induces the 
downstream “apoptosis-effector caspases” (ie, caspase 3). 
As shown in Figures 6 and S6, the anisamide-targeted 
AuNR.EPI complex plus laser irradiation significantly 
improved the activity of caspase 9/3 relative to either of 
monotherapies. This synergistic apoptotic effect confirmed 
the hypothesis that the laser-based thermal activation 
induced by anisamide-targeted AuNRs can enhance the 
sensitivity of tumor cells to EPI.
Due to the apoptotic effects, targeted AuNR.EPI complex 
(MR =5) with laser treatment significantly slowed down the 
proliferation of PC-3 cells (P,0.01; ,50% and .70% reduc-
tions after 24 hours and 48 hours incubation, respectively) 
(Figure 7); in contrast, less cytotoxicity was observed with 
either of monotherapies. In addition, the targeted complex 
achieved significantly higher cell death relative to its non-
targeted counterpart (Figure 7), further indicating the func-
tion of anisamide targeting ligand.
As AuNRs alone did not cause any cytotoxicity (Figure 7), 
the in vitro anticancer effect achieved with anisamide-targeted 
AuNR.EPI complex plus laser irradiation was most likely 
due to the synergistic apoptotic effects.
In vivo antitumor efficacy
Recently, the combination of chemotherapy with AuNR-
mediated PTT has been confirmed to be more effective 
than either of the individual therapies.9–16 In this study, 
the anisamide-targeted AuNR-based CPTT efficacy was 
assessed in subcutaneous PC-3 xenograft mice following 
intratumoral injection (n=4) (Figure 8A and B). Results show 
that both Au
800
-CTAB-PEG-AA complex containing EPI 
(MR =5) and Au
800
-CTAB-PEG-AA with laser stimulation 
significantly (P,0.05) slowed down tumor growth relative 
to the saline control group. In addition, when stimulated with 
laser irradiation, the Au
800
-CTAB-PEG-AA.EPI complex 
further (P,0.05) retarded tumor growth compared to either 
of monotherapies. Records of mouse body weight demon-
strated no significant loss compared to the saline control 
group over the treatment period (Figure 8C), indicating the 
absence of AuNR-induced toxicity. These results indicate 
that the combination of anisamide-targeted AuNR-based 
PTT and simultaneous application of EPI may provide the 
synergistic therapeutic potential for the treatment of sigma 
receptor-positive prostate carcinoma.
Conclusion
A range of negatively charged anisamide-targeted PEGylated 
AuNRs (namely Au-CTAB-PAA-PEG-AA) were developed 
for PTT and simultaneous delivery of EPI in the treatment 




effectively complex EPI via the electrostatic interaction, and 
the resultant complexation (Au
800
-CTAB-PAA-PEG-AA.




strated efficient release of EPI in acidic buffer solution but 
avoided burst drug release in physiological buffer solution, 
demonstrating the role of anisamide-targeted AuNRs as 
the controlled drug delivery system. The in vitro studies 
showed cell-specific internalization indicating the function 
of the anisamide targeting ligand. When stimulated with 
desired laser irradiation, the anisamide-targeted AuNR.EPI 
complex demonstrated in vivo synergistic antitumor effects 
in PC-3 xenografted mice compared to either of individual 
monotherapies, without showing significant toxicity. These 
results imply that the anisamide-targeted AuNR vector pro-
vides a promising strategy for combination of chemotherapy 
and PTT in the treatment of sigma receptor-positive cancer.
Figure 7 cell viability measured in Pc-3 cells after 24 hours and 48 hours of 
treatment with anisamide-targeted auNr.ePI complex plus laser irradiation (808 nm 
at 2.5 W/cm2 for 0.5 minutes) using MTT assay (n=3). ePI =1 µM; auNr = au800-
cTaB-Paa-Peg; auNr.ePI = au800-cTaB-Paa-Peg.ePI (Mr =5); auNr-aa = 
au800-cTaB-Paa-Peg-aa; and auNr-aa.ePI = au800-cTaB-Paa-Peg-aa.ePI 
(Mr =5). *P,0.05 and **P,0.01 relative to ePI; #P,0.05 and ##P,0.01 relative to 
auNr.ePI; $P,0.0 relative to auNr-aa.ePI.
Abbreviations: auNrs, gold nanorods; ePI, epirubicin; cTaB, hexadecyltrimethyl-
ammonium bromide; Paa, poly(acrylic acid); aa, anisamide; Peg, polyethylene 






































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1






This work was supported by the Outstanding Youth Founda-
tion from the Department of Science and Technology, Jilin 
Province, China (20170520046JH), the Start-Up Research 
Grant Program from Jilin University (451170301168, 
451160102052, 419080500667), and the Fundamental 
Research Funds for the Central Universities, China. Jin Pei, 
Kamil Rahme and Jianfeng Guo are co-corresponding authors.
Disclosure
The authors report no conflicts of interest in this work.
References
1. Huang X, Neretina S, El-Sayed MA. Gold nanorods: from synthesis 
and properties to biological and biomedical applications. Adv Mater. 
2009;21(48):4880–4910.
2. Lal S, Clare SE, Halas NJ. Nanoshell-enabled photothermal cancer ther-
apy: impending clinical impact. Acc Chem Res. 2008;41(12):1842–1851.
3. Chen J, Glaus C, Laforest R, et al. Gold nanocages as photothermal 
transducers for cancer treatment. Small. 2010;6(7):811–817.
 4. Ali MR, Rahman MA, Wu Y, et al. Efficacy, long-term toxicity, and 
mechanistic studies of gold nanorods photothermal therapy of cancer in 
xenograft mice. Proc Natl Acad Sci U S A. 2017;114(15):E3110–E3118.
 5. Alkilany AM, Thompson LB, Boulos SP, Sisco PN, Murphy CJ. 
Gold nanorods: their potential for photothermal therapeutics and drug 
delivery, tempered by the complexity of their biological interactions. 
Adv Drug Deliv Rev. 2012;64(2):190–199.
 6. Guo J, Rahme K, He Y, Li LL, Holmes JD, O’Driscoll CM. Gold 
nanoparticles enlighten the future of cancer theranostics. Int J Nano-
medicine. 2017;12:6131–6152.
 7. Chen R, Wang X, Yao X, Zheng X, Wang J, Jiang X. Near-IR-triggered 
photothermal/photodynamic dual-modality therapy system via chitosan 
hybrid nanospheres. Biomaterials. 2013;34(33):8314–8322.
 8. Jayaram DT, Ramos-Romero S, Shankar BH, et al. In vitro and in vivo 
demonstration of photodynamic activity and cytoplasm imaging through 
tpe nanoparticles. ACS Chem Biol. 2016;11(1):104–112.
 9. Cheng FY, Su CH, Wu PC, Yeh CS. Multifunctional polymeric 
nanoparticles for combined chemotherapeutic and near-infrared pho-
tothermal cancer therapy in vitro and in vivo. Chem Commun. 2010; 
46(18):3167–3169.
 10. Kuo TR, Hovhannisyan VA, Chao YC, et al. Multiple release kinetics 
of targeted drug from gold nanorod embedded polyelectrolyte conju-
gates induced by near-infrared laser irradiation. J Am Chem Soc. 2010; 
132(40):14163–14171.
Figure 8 (A) Pc-3 xenograft mice (n=4 per group) following intratumoral injections of au800-cTaB-Paa-Peg-aa.ePI (Mr 5; ~0.5 mg/kg ePI) followed by 808 nm laser 
stimulation at 2.5 W/cm2 for 2 minutes on days 1, 3, 5, 7, and 9. (B) The image of tumors was obtained at day 17. (C) at predetermined days, body weight (mean ± sD, n=4) 
was recorded to determine in vivo toxicity (*P,0.05).
Abbreviations: auNrs, gold nanorods; ePI, epirubicin; cTaB, hexadecyltrimethylammonium bromide; Paa, poly(acrylic acid); aa, anisamide; Peg, polyethylene glycol; 






































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1





 11. Hribar KC, Lee MH, Lee D, Burdick JA. Enhanced release of small 
molecules from near-infrared light responsive polymer-nanorod com-
posites. ACS Nano. 2011;5(4):2948–2956.
 12. Ren F, Bhana S, Norman DD, et al. Gold nanorods carrying paclitaxel for 
photothermal-chemotherapy of cancer. Bioconjug Chem. 2013;24(3): 
376–386.
 13. Monem AS, Elbialy N, Mohamed N. Mesoporous silica coated gold 
nanorods loaded doxorubicin for combined chemo-photothermal 
therapy. Int J Pharm. 2014;470(1–2):1–7.
 14. Hua H, Zhang N, Liu D, et al. Multifunctional gold nanorods and 
docetaxel-encapsulated liposomes for combined thermo- and chemo-
therapy. Int J Nanomedicine. 2017;12:7869–7884.
 15. Chen J, Li X, Zhao X, et al. Doxorubicin-conjugated pH-responsive 
gold nanorods for combined photothermal therapy and chemotherapy 
of cancer. Bioact Mater. 2018;3(3):347–354.
 16. Wang X, Gao S, Qin Z, et al. Evans blue derivative-functionalized gold 
nanorods for photothermal Therapy-Enhanced tumor chemotherapy. 
ACS Appl Mater Interfaces. 2018;10(17):15140–15149.
 17. Vilner BJ, John CS, Bowen WD. Sigma-1 and sigma-2 receptors are 
expressed in a wide variety of human and rodent tumor cell lines. 
Cancer Res. 1995;55(2):408–413.
 18. Banerjee R, Tyagi P, Li S, Huang L. Anisamide-targeted stealth lipo-
somes: a potent carrier for targeting doxorubicin to human prostate 
cancer cells. Int J Cancer. 2004;112(4):693–700.
 19. Guo J, Ogier JR, Desgranges S, Darcy R, O’Driscoll C. Anisamide-
targeted cyclodextrin nanoparticles for siRNA delivery to prostate 
tumours in mice. Biomaterials. 2012;33(31):7775–7784.
 20. Nikoobakht B, El-Sayed MA. Preparation and growth mechanism 
of gold nanorods (NRS) using seed-mediated growth method. Chem 
Mater. 2003;15(10):1957–1962.
 21. Fitzgerald KA, Rahme K, Guo J, Holmes JD, O’Driscoll CM. 
Anisamide-targeted gold nanoparticles for siRNA delivery in prostate 
cancer – synthesis, physicochemical characterisation and in vitro evalu-
ation. J Mater Chem. 2016;4(13):2242–2252.
 22. Hussein E, Zagho M, Nasrallah G, Elzatahry A. Recent advances 
in functional nanostructures as cancer photothermal therapy. Int J 
Nanomed. 2018;13:2897–2906.
 23. Riley RS, Day ES. Gold nanoparticle-mediated photothermal therapy: 
applications and opportunities for multimodal cancer treatment. 
WIREs Nanomed Nanobiotechnol. 2017;9(4):e1449.
 24. Cabral RM, Baptista PV. Anti-cancer precision theranostics: a 
focus on multifunctional gold nanoparticles. Expert Rev Mol Diagn. 
2014;14(8):1041–1052.
 25. Kim FJ, Maher CM. Sigma1 pharmacology in the context of cancer. 
Handb Exp Pharmacol. 2017;244:237–308.
 26. Rousseaux CG, Greene SF. Sigma receptors [σRs]: biology in nor-
mal and diseased states. J Recept Signal Transduct Res. 2016;36(4): 
327–388. 
 27. Chen Y, Bathula SR, Yang Q, Huang L. Targeted nanoparticles deliver 
siRNA to melanoma. J Invest Dermatol. 2010;130(12):2790–2798.
 28. Wang Y, Su HH, Yang Y, et al. Systemic delivery of modified mRNA 
encoding herpes simplex virus 1 thymidine kinase for targeted cancer 
gene therapy. Mol Ther. 2013;21(2):358–367.
 29. Rodriguez BL, Blando JM, Lansakara-P DSP, Kiguchi Y, Digiovanni J, 
Cui Z. Antitumor activity of tumor-targeted RNA replicase-based 
plasmid that expresses interleukin-2 in a murine melanoma model. 
Mol Pharm. 2013;10(6):2404–2415.
 30. Fitzgerald KA, Malhotra M, Gooding M, et al. A novel, anisamide-
targeted cyclodextrin nanoformulation for siRNA delivery to prostate 
cancer cells expressing the sigma-1 receptor. Int J Pharm. 2016;499(1–2): 
131–145.
 31. Evans JC, Malhotra M, Fitzgerald KA, et al. Formulation and evalu-
ation of Anisamide-Targeted amphiphilic cyclodextrin nanoparticles 
to promote therapeutic gene silencing in a 3D prostate cancer bone 
metastases model. Mol Pharm. 2017;14(1):42–52.
 32. Liu Q, Zhu H, Tiruthani K, et al. Nanoparticle-Mediated trapping of 
Wnt family member 5A in tumor microenvironments enhances immu-
notherapy for B-Raf proto-oncogene mutant melanoma. ACS Nano. 
2018;12(2):1250–1261.
 33. Song W, Shen L, Wang Y, et al. Synergistic and low adverse effect 
cancer immunotherapy by immunogenic chemotherapy and locally 
expressed PD-L1 trap. Nat Commun. 2018;9(1):2237.
 34. Amreddy N, Muralidharan R, Babua A, et al. Tumor-targeted and pH-
controlled delivery of doxorubicin using gold nanorods for lung cancer 
therapy. Int J Nanomed. 2015;10:6773–6788.
 35. Khasraw M, Bell R, Dang C. Epirubicin: is it like doxorubicin in breast 
cancer? A clinical review. The Breast. 2012;21(2):142–149.
 36. Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy 
for improving nanoparticle-based drug and gene delivery. Adv Drug 
Deliv Rev. 2016;99(Pt A):28–51.
 37. Kolate A, Baradia D, Patil S, Vhora I, Kore G, Misra A. PEG – a versa-
tile conjugating ligand for drugs and drug delivery systems. J Control 
Release. 2014;192:67–81.
 38. Marrazzo A, Fiorito J, Zappalà L, et al. Antiproliferative activity 
of phenylbutyrate ester of haloperidol metabolite II [(±)-MRJF4] in 
prostate cancer cells. Eur J Med Chem. 2011;46(1):433–438.
39. Evans JC, Malhotra M, Fitzgerald KA, et al. Formulation and evalu-
ation of Anisamide-Targeted amphiphilic cyclodextrin nanoparticles 
to promote therapeutic gene silencing in a 3D prostate cancer bone 
metastases model. Mol Pharm. 2017;14(1):42–52.
 40. Boyer D, Tamarat P, Maali A, Lounis B, Orrit M. Photothermal imaging 
of nanometer-sized metal particles among scatterers. Science. 2002; 
297(5584):1160–1163.
 41. Guo J, O’Driscoll CM, Holmes JD, Rahme K. Bioconjugated gold 
nanoparticles enhance cellular uptake: a proof of concept study for 
siRNA delivery in prostate cancer cells. Int J Pharm. 2016;509(1–2): 
16–27.
 42. Ding W, Liu Y, Li Y, et al. Water-soluble gold nanoclusters with pH-
dependent fluorescence and high colloidal stability over a wide pH 
range via co-reduction of glutathione and citrate. RSC Adv. 2014;4(43): 
22651–22659.
 43. Freese C, Unger RE, Deller RC, et al. Uptake of poly(2-hydroxy-
propylmethacrylamide)-coated gold nanoparticles in microvascular 
endothelial cells and transport across the blood–brain barrier. Biomac-
romolecules. 2013;1(8):824–833.
 44. Ju RJ, Zeng F, Liu L, et al. Destruction of vasculogenic mimicry chan-
nels by targeting epirubicin plus celecoxib liposomes in treatment of 
brain glioma. Int J Nanomedicine. 2016;11:1131–1146.
 45. Lee CM, Tannock IF. Inhibition of endosomal sequestration of basic 
anticancer drugs: influence on cytotoxicity and tissue penetration. Br 
J Cancer. 2006;94(6):863–869.
 46. Hurwitz SJ, Terashima M, Mizunuma N, Slapak CA. Vesicular anthra-
cycline accumulation in doxorubicin-selected U-937 cells: participation 
of lysosomes. Blood. 1997;89(10):3745–3754.
 47. Yang X, Fan B, Gao W, et al. Enhanced endosomal escape by photo-
thermal activation for improved small interfering RNA delivery and 
antitumor effect. Int J Nanomedicine. 2018;13:4333–4344.
 48. Vermeulen LMP, Fraire JC, Raes L, et al. Photothermally triggered 
endosomal escape and its influence on transfection efficiency of 
Gold-Functionalized JetPEI/pDNA nanoparticles. Int J Mol Sci. 
2018;19(8):pii: E2400.
 49. Adams JM, Cory S. The bcl-2 apoptotic switch in cancer development 
and therapy. Oncogene. 2007;26(9):1324–1337.
 50. Bredlau AL, McCrackin MA, Motamarry A, et al. Thermal therapy 
approaches for treatment of brain tumors in animals and humans. Crit 
Rev Biomed Eng. 2016;44(6):443–457.
 51. Schaaf L, Schwab M, Ulmer C, et al. Hyperthermia synergizes with 







































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1






synthesis of auNr-cTaB with 
longitudinal wavelengths of ~700, 725, 
and 765 nm
Synthesis of gold nanorods (AuNRs) with longitudinal 
wavelength (~700 nm): About 75 mL of 0.2 M hexadecyl-
trimethylammonium bromide (CTAB) solution was added 
to 0.485 mL of 12.36 mM AgNO
3
 solution at 25°C, which 
was followed by the addition of 75 mL of 0.001 M HAuCl
4
. 






 was added, and the 
solution color changed from dark yellow to colorless. Sub-
sequently, 0.108 mL of the seed solution was added to the 
growth solution at 27°C–30°C. The solution color changed to 
dark blue within 5–15 minutes. The growth medium was kept 
undisturbed at 27°C–30°C for 22 hours. The obtained AuNR-
CTAB (~700 nm) complex was washed three times with 
deionized water by centrifugation (12,500 rpm, 5 minutes) 
prior to the following experiments.
Synthesis of AuNRs with longitudinal wavelength 
(~725 nm): About 75 mL of 0.2 M CTAB solution was 
added to 2.184 mL of 12.36 mM AgNO
3
 solution at 25°C, 
which was followed by the addition of 75 mL of 0.001 M 
HAuCl
4






 was added, 
and the solution color changed from dark yellow to colorless. 
Subsequently, 0.108 mL of the seed solution was added to the 
growth solution at 27°C–30°C. The solution color changed 
to dark blue within 10–20 minutes. The growth medium was 
kept undisturbed at 27°C–30°C for 22 hours. The obtained 
AuNR-CTAB (~725 nm) was washed three times with 
deionized water by centrifugation (12,500 rpm, 5 minutes) 
prior to the following experiments.
Synthesis of AuNRs with longitudinal wavelength 
(~765 nm): About 75 mL of 0.2 M CTAB solution was 
added to 3 mL of 4 mM AgNO
3
 solution at 25°C, which 
was followed by the addition of 75 mL of 0.001 M HAuCl
4
. 






 was added, and 
the solution color changed from dark yellow to colorless. 
Subsequently, 0.108 mL of the seed solution was added to the 
growth solution at 27°C–30°C. The solution color changed 
to deep red within 15–30 minutes. The growth medium was 
kept undisturbed at 27°C–30°C for 22 hours. The obtained 
AuNR-CTAB (~765 nm) was washed three times with 
deionized water by centrifugation (12,500 rpm, 5 minutes) 
prior to the following experiments.
Figure S1 TeM images of au700-cTaB, au725-cTaB, and au765-cTaB (scale bar =50 nm). 
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Figure S2 1h NMr spectrum of anisic-Nhs.
Abbreviations: NMr, nuclear magnetic resonance; Nhs, N-hydroxysuccinimide.
Figure S3 1h NMr spectrum of sh-Peg5000-aa.
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Figure S4 stability of au800-cTaB-Paa-Peg-aa.ePI complex (Mr =5) incubated in the saline at 4°c (left tube in the image) and 37°c (right tube in the image) for 4, 24, and 
48 hours. In addition, the size distribution results obtained from dynamic light scattering demonstrated that no aggregation occurred following the incubation.
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Figure S5 (A) Kinetic changes of surface temperature after the laser irradiation (808 nm, 2.5 W/cm2) of PBs, ePI, au800-cTaB-Paa-Peg-aa (auNr-aa), and auNr-aa.
ePI complex for 4.5 minutes. (B) Thermographic images of PBs, ePI, auNr-aa, and auNr-aa.ePI complex after the laser stimulation (808 nm, 2.5 W/cm2) for 4.5 minutes. 
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Figure S6 The expression of caspase 3, cleaved caspase 3, caspase 9, cleaved caspase 9, Bax, and Bcl-2 was determined using Western blotting (n=3) relative to β-actin. 
*P,0.05, **P,0.01, ***P,0.001, ****P,0.0001 relative to the untreated group; &P,0.05 relative to the auNr-aa.ePI group.
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